Market Overview

UPDATE: Oppenheimer Holdings Downgrades Celgene Corporation to Perform, Removes PT

Share:
Related CELG
Analysts Confident In Acceleron Pharma's Drug Trial Outcomes
Biotechs Are Ripping Following IPAB Ruling
How Does Brexit Affect Biotech Stocks? Wall Street Weighs In (Investor's Business Daily)

In a report published Monday, Oppenheimer Holdings downgraded its rating on Celgene Corporation (NASDAQ: CELG) from Outperform to Perform, and removed its $77.00 price target.

Oppenheimer noted, “We are downgrading Celgene from Outperform to Perform and removing our $77 price target. We believe that the company is trading in line with its peers (15x our 2014E GAAP EPS of $5.36). Although we estimate Revlimid will grow 14%/yr over the next three years, we believe that Celgene is likely to make several substantial acquisitions over the next 1-2 years in order to extend top-line growth beyond Revlimid. We analyzed Celgene's acquisitions of Pharmion, Abraxis, and Gloucester and came to the conclusion that these acquisitions had limited, if any, return based on the acquisition price. Given the recent strong performance for the entire biotech sector, we believe that it will be more difficult for Celgene to find good acquisitions.”

Celgene Corporation closed on Friday at $78.42.

Latest Ratings for CELG

DateFirmActionFromTo
Jun 2016BTIG ResearchDowngradesBuyNeutral
Apr 2016Credit SuisseMaintainsOutperform
Apr 2016BMO CapitalInitiates Coverage onOutperform

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Oppenheimer HoldingsAnalyst Color Downgrades Analyst Ratings

 

Related Articles (CELG)

View Comments and Join the Discussion!